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De-escalation of empirical antibiotic therapy is often included in antimicrobial stewardship programs in critically ill patients,
but differences in target attainment when antibiotics are switched are rarely considered. The primary objective of this study was
to compare the fractional target attainments of contemporary dosing of empirical broad-spectrum -lactam antibiotics and nar-
rower-spectrum antibiotics for a number pathogens for which de-escalation may be considered. The secondary objective was to
determine whether alternative dosing strategies improve target attainment. We performed a simulation study using published
population pharmacokinetic (PK) studies in critically ill patients for a number of broad-spectrum -lactam antibiotics and nar-
rower-spectrum antibiotics. Simulations were undertaken using a data set obtained from critically ill patients with sepsis with-
out absolute renal failure (n 49). The probability of target attainment of antibiotic therapy for different microorganisms for
which de-escalation was applied was analyzed. EUCASTMIC distribution data were used to calculate fractional target attain-
ment. The probability that therapeutic exposure will be achieved was lower for the narrower-spectrum antibiotics with conven-
tional dosing than for the broad-spectrum alternatives and could drastically be improved with higher dosages and different
modes of administrations. For a selection of microorganisms, the probability that therapeutic exposure will be achieved was
overall lower for the narrower-spectrum antibiotics using conventional dosing than for the broad-spectrum antibiotics.
Provision of antibiotic therapy that is timely and of an appro-priate spectrum is one of the mainstays of treatment (1, 2).
This has led to the widespread use of broad-spectrum antibiotic
therapy for the empirical treatment of infections. After identifica-
tion of the causativemicroorganism, antibiotic therapy is typically
adapted to the susceptibility profile of the microorganism, with a
preference to change therapy to narrower-spectrum agents in or-
der to decrease selective pressure for resistant pathogens. This
process is called antibiotic de-escalation and is considered an im-
portant element in antibiotic stewardship programs (3–5).
Although the timing and adequacy of the antibiotic therapy
remain crucial, recent data hint at the importance of antibiotic
dosing and exposure on clinical outcome (6). Changes in the
physiology of the critically ill alter the pharmacokinetics (PKs) of
-lactam antibiotics, with many patients being at risk of being
underdosed (7, 8). Attainment of PK/pharmacodynamic (PD)
targets associated with efficacy is also dependent on the suscepti-
bility of the pathogen and varies across antibiotic classes, an ele-
ment that is rarely considered (8).
Although de-escalation of antibiotic therapy is a key element in
many antibiotic stewardship programs, the possible change in
PK/PD target attainment in de-escalation has not yet been consid-
ered. De-escalation has been associated with improved outcomes
in many observational (nonrandomized) studies; however, these
findings may be due to selection bias, as de-escalation may be
mainly performed in patients who are improving (9, 10). A recent
randomized controlled study performed by Leone et al. (11)
found that de-escalation to narrower-spectrumantibiotics did not
reduce patient intensive care unit (ICU) length of stay and was
associated with an increased number of antibiotic days in patients
in whom antibiotic therapy had been de-escalated. The authors
also reported that superinfections were more frequent in patients
in whom antibiotic therapy had been de-escalated, with about half
of the superinfections being caused by the same pathogens that
caused the initial infection (11).
Based on these observations, we hypothesized that PK/PD target
attainment after de-escalationmay be lower than that with empirical
therapy, even when the pathogen is reported to be susceptible to the
de-escalation antibiotic. The primary objective of this study was to
compare the probability that PK/PD targets will be achieved with
conventional dosing of empirical broad-spectrum antibiotics and
narrower-spectrum antibiotics for a number of pathogens for which
de-escalation may occur. The secondary objective was to determine
whetherPK/PDtarget attainmentcouldbe improvedwithalternative
dosing strategies for both types of antibiotics.
MATERIALS AND METHODS
We performed an in silico (computer) simulation study using published
population pharmacokinetic studies in critically ill patients for a number
of broad-spectrum -lactam antibiotics (meropenem and piperacillin-
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tazobactam) and narrower-spectrum antibiotics often used in de-escala-
tion (amoxicillin-clavulanic acid, cefuroxime, flucloxacillin, cefazolin,
and cefepime), as reported in recent studies (12–18). Protein binding was
assumed to be 17% for amoxicillin, 33% for cefuroxime, and 10% for
cefepime (19). Protein binding formeropenem is negligible, and themod-
els for piperacillin, flucloxacillin, and cefazolin were based on measured
free concentrations, so no correction was necessary.
We simulated 30-min infusions for all antibiotics, as intermittent in-
fusion remains the most commonmethod of administration in ICUs (6).
Treatment with the broad-spectrum empirical antibiotics was also simu-
lated as extended and continuous infusions, as these administration tech-
niques are becoming more common as a way to maximize PK/PD target
attainment (20). For amoxicillin-clavulanic acid and piperacillin-tazo-
bactam, doses for the amoxicillin or piperacillin component only were
simulated because the PK/PD targets for the -lactamase inhibitors in
these combinations remain unclear. The simulated dosages were derived
from the package inserts and are summarized in Table 1. PK/PD target
attainment of higher dosages and alternative dosing strategies were also
investigated for the narrower-spectrum antibiotics. The simulated dos-
ages are summarized in Table 2.
The simulations were performed using NONMEM (version 7.3.0;
Globomax LLX, Hanover, MD, USA). A digital FORTRAN compiler was
used, and the runs were executed usingWings for NONMEM (http://wfn
.sourceforge.net). For each antibiotic, 1,000 Monte Carlo simulations
were undertaken using a patient data set (n 49) with various creatinine
clearances (range, 22 to 230 ml/min) and the parameters from the pub-
lished covariate model. This data set was obtained from a previous study
conducted in a tertiary referral ICU (21). Patients were eligible for enroll-
ment if they were between 18 and 80 years of age and were receiving
piperacillin-tazobactam for the treatment of sepsis (defined as a presumed
or confirmed infection, while manifesting a systemic inflammatory re-
sponse syndrome). Patients were excluded if they did not have an intra-
arterial line, had significant renal impairment (defined by a plasma creat-
inine concentration of171mol/liter or the need for renal replacement
therapy), or had a history of allergy to piperacillin or iodine. This there-
fore represents a convenience sample of critically ill septic patients with-
out significant renal impairment. The patient characteristics are summa-
rized in Table 3.
Using the simulated concentration-time profiles, the time for which
the free antibiotic concentration exceeds theMIC (fTMIC)was calculated
for each simulated subject using linear interpolation. The PK/PD target
was set at 40% fTMIC for carbapenems, 50% fTMIC for penicillins, and
65% fTMIC for cephalosporins, and this was defined as the conservative
PK/PD target, which is the target found to be associated with themaximal
effect in animalmodels (22). There are almost nodata onwhich targets are
needed to treat infections in critically ill patients; however, there are some
retrospective studies that have found that higher targets may be needed to
treat serious infections in this patient population. Therefore, we per-
formed an additional simulation with a higher target of 100% fTMIC for
all antibiotics (23, 24).
The microorganisms used in this simulation study were Escherichia
coli, Staphylococcus aureus, Streptococcus spp.,Klebsiella pneumoniae,Hae-
mophilus influenzae, Citrobacter freundii, Morganella morganii, and Pro-
teusmirabilis, as these aremicroorganisms forwhich de-escalation ismore
commonly performed (9, 11, 25–27).
MIC distribution data for each antibiotic for the pathogens indicated
above were obtained from the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) to determine fractional target attain-
ment (FTA) (28). This identifies the likely success of treatment by com-
paring the achievement of the PK/PD target against an MIC distribution.
Microorganisms with an MIC above the clinical susceptible breakpoint
TABLE 1 Simulated intravenous dosages of antibiotics
Antibiotic Dosage simulation
Meropenem 1 g every 8 h as an intermittent infusion
1 g every 8 h as a 4-h extended infusion
3 g/day as a continuous infusion
Piperacillin 4 g every 8 h as an intermittent infusion
4 g every 8 h as a 4-h extended infusion
12 g/day as a continuous infusion
4 g every 6 h as an intermittent infusion
4 g every 6 h as a 3-h extended infusion
16 g/day as a continuous infusion
Cefepime 1 g every 12 h as an intermittent infusion
2 g every 12 h as an intermittent infusion for S. aureus
infections
Amoxicillin 1 g every 6 h as an intermittent infusion
Cefuroxime 1.5 g every 8 h as an intermittent infusion
Flucloxacillin 1 g every 6 h as an intermittent infusion
Cefazolin 1 g every 8 h as an intermittent infusion
TABLE 2 Simulated dosages for the de-escalation antibiotics using
higher dosages and alternative dosing strategies
Antibiotic Dosage simulation
Amoxicillin 1 g every 4 h as an intermittent infusion
1 g every 4 h as a 2-h extended infusion
6 g/day as a continuous infusion
Cefuroxime 1.5 g every 6 h as an intermittent infusion
1.5 g every 6 h as a 3-h extended infusion
6 g/day as a continuous infusion
Flucloxacillin 2 g every 6 h as an intermittent infusion
2 g every 6 h as a 3-h extended infusion
8 g/day as a continuous infusion
Cefazolin 1 g every 6 h as an intermittent infusion
1 g every 6 h as a 3-h extended infusion
4 g/day as a continuous infusion
Cefepime 2 g every 8 h as an intermittent infusion
1 g every 4 h as an intermittent infusion
4 g/day as a continuous infusion
TABLE 3 Patient characteristicsa
Characteristic Value
No. of males/no. of females 27/22
Age (yr) 46 (33–64)
Ht (m) 1.70 (1.63–1.80)
Wt (kg) 84 (73–95)
BMI (kg/m2) 29.4 (25.1–33.3)
Creatinine clearance (ml/min) 105 (74–143)
APACHE II score 17 (14–25)
SOFA score 6 (5–9)
Serum urea concn (mmol/liter) 6.2 (3.9–8.7)
Serum creatinine concn (mol/liter) 73 (55–97)
Serum albumin concn (g/liter) 21 (20–24)
8-h creatinine clearance (ml/min) 112 (76–142)
% of patients mechanically
ventilated
93.4
a Unless indicated otherwise, data are reported as the median (interquartile range).
BMI, body mass index; APACHE II, Acute Physiology and Chronic Health Evaluation;
SOFA, sequential organ failure assessment.
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were not included in the FTA calculation because ongoing prescription
would not be supported by the susceptibility testing upon which the de-
escalation is based.
RESULTS
Probability of attainment for the conservative PK/PD target.
The results of the simulations for the conservative target are
shown in Table 4. The FTA for the conservative target for the
broad-spectrum antibiotics administered as an intermittent infu-
sion at high doses (piperacillin-tazobactam at 4 g every 6 h and
meropenem at 1 g every 8 h) was95% for all simulations, reach-
ing 100% when administered as an extended or continuous infu-
sion. The FTA for piperacillin-tazobactam at a lower dose (4 g
every 8 h) was slightly lower, with the lowest FTA being 89% forK.
pneumoniae, although this increased to 100% when administered
as a continuous or extended infusion.
For the narrower-spectrum antibiotics in conventional dosing,
the FTA was lower than that for the broad-spectrum antibiotics.
As shown in Table 4, the FTA for amoxicillin-clavulanic acid (1 g
every 6 h) ranged from 85% (E. coli) to 100% depending on the
microorganism. The lowest FTA for cefuroxime (1.5 g every 8 h)
was 65% for E. coli. Flucloxacillin (1 g every 6 h), cefepime (2 g
every 12 h), and cefazolin (1 g every 8 h) had FTAs of, respectively,
74, 88, and 90% for oxacillin-susceptible S. aureus.
Probability of target attainment for the higher 100% fT>MIC
target. The FTAs for the higher target of 100% fTMIC are shown
in Table 4. For the broad-spectrum antibiotics, only the continu-
ous infusion of meropenem and piperacillin-tazobactam (pipera-
cillin doses of 12 and 16 g/day) reached a 100%FTA for all studied
microorganisms.
The FTA for meropenem (1 g every 8 h) administered as a
TABLE 4 FTA for different antibiotics, microorganisms, dosages, and modes of administration using the both the conservative and the high PK/PD
targetsa
Antibiotic Dosing
FTA (%)
Oxacillin-
susceptible
S. aureus
Streptococcus
spp.
K.
pneumoniae
H.
influenzae C. freundii M. morganii P. mirabilis E. coli
Low High Low High Low High Low High Low High Low High Low High Low High
Meropenem 3 g, CI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
1 g q8h, EI 99 87 100 100 100 93 100 93 99 92 99 89 100 92 100 97
1 g q8h, II 99 64 100 100 100 72 100 73 99 70 99 66 100 70 100 88
Piperacillin- tazobactam 16 g, CI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
4 g q6h, EI 100 94 100 100 100 87 100 100 100 88 100 96 100 96 100 91
4 g q6h, II 98 87 100 100 95 76 100 100 96 78 99 91 99 91 97 81
12 g, CI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
4 g q8h, EI 100 88 100 100 100 77 100 100 100 79 100 100 100 92 100 82
4 g q8h, II 95 78 100 100 89 62 100 100 90 65 97 83 97 84 92 69
Cefepime 1 g q12h, II 76 54 100 97 100 99 100 99 100 100 100 100 100 100 100 100
2 g q12h, II 88 69 100 100 100 100 100 100 100 100 100 100 100 100 100 100
2 g q8h, II 98 90 100 100 100 100 100 100 100 100 100 100 100 100 100 100
1 g q4h, II 99 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100
4 g, CI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Amoxicillin- clavulanic
acid
1 g q6h, II 96b 83b 100b 100b 90 77 98b 89b 91 74 89b 73b 98 87 85 66
1 g q4h, II 99b 92b 100b 100b 95 86 99b 97b 96 86 95b 85b 99 95 92 80
1 g q4h, EI 100b 95b 100b 100b 95 90 100b 98b 100 90 100b 89b 100 97 100 85
6 g, CI 100b 100b 100b 100b 99 99 100b 100b 99 99 98b 98b 100 100 98 98
Cefuroxime 1.5 g q8h, II 86 61 100 100 73 53 88 71 66 46 83 64 65 45
1.5 g q6h, II 94 81 100 100 84 67 95 84 79 61 92 78 78 60
1.5 g q6h, EI 99 90 100 100 95 79 100 92 93 73 99 88 92 72
6 g CI 100 100 100 100 99 99 100 100 98 98 99 99 98 98
Flucloxacillin 1 g q6h, II 74 36
2 g q6h, II 87 54
2 g q6h, EI 100 71
8 g, CI 100 100
Cefazolin 1 g q8h, II 90 77
1 g q6h, II 96 89
1 g q6h, EI 100 93
4 g, CI 100 100
a Low, FTA using the conservative PK/PD target of 40% fTMIC for carbapenems, 50% fTMIC for penicillins, and 60% fTMIC for cephalosporins; high, FTA using the high PK/
PD target of 100% fTMIC; CI, continuous infusion; EI, extended infusion; II, intermittent infusion; q8h, every 8 h; q6h, every 6 h; q4h, every 4 h. Boldface indicates FTA of90%.
b The MIC distribution of amoxicillin was used, as no MIC distribution of amoxicillin-clavulanic acid was available.
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30-min infusion ranged from 100% (Streptococcus spp.) to 64%
(oxacillin-susceptible S. aureus), which increased to 87% when
administered as a 4-h infusion and to 100%when administered as
a continuous infusion.
Similarly, for piperacillin-tazobactam, an increase in the infu-
sion time improved the FTA. When administered at 4 g every 6 h,
the lowest FTAwas 76% forK. pneumoniae. It was 87% for the 3-h
infusion and increased to 100% for the continuous infusion. At
the lower dose, the FTA was only 62% for K. pneumoniae, 77%
when administered as a 4-h extended infusion, and 100% when
administered as a continuous infusion.
For the de-escalation antibiotics, the FTA was also lower than
that for the conservative target. The lowest FTA for amoxicillin-
clavulanic acid (1 g every 6 h) was 66% for E. coli, and the lowest
FTA for cefuroxime was 45% for the standard dose of 1.5 g every 8
h for E. coli. The FTAs for flucloxacillin (1 g every 6 h) and
cefepime (2 g every 12 h) for oxacillin-susceptible S. aureus were
similarly poor (36% and 69%, respectively), but the FTA for cefa-
zolin (1 g every 8 h) was slightly better at 77%.
Fractional target attainment when administering higher
dosages or using alternative modes of administration for the
narrower-spectrum antibiotics. The FTAs obtained using the
conservative targets for the higher dosages/alternative modes of
administration are shown in Table 4. Increasing the dose for
amoxicillin-clavulanic acid from 1 g every 6 h to 1 g every 4 h
increased the FTA using the conservative target for E. coli from
85% to 92%, and the FTA was increased to 100% when an ex-
tended or continuous infusion of 6 g was used. Similarly, for ce-
furoxime, increasing the dose and increasing the infusion time
improved the FTA from 65% for E. coli (conventional dose of 1.5
g every 8 h) to 98%when administered as a continuous infusion of
6 g. For flucloxacillin, increasing the dose from 1 g every 6 h to 2 g
every 6 h as an extended or continuous infusion increased the FTA
for oxacillin-susceptible S. aureus from 74 to 100%. For cefazolin
and cefepime, a continuous infusion of 4 g increased the FTA
against oxacillin-susceptible S. aureus from 88% (cefepime at 2 g
every 12 h) and 90% (cefazolin at 1 g every 8 h) to 100% for both
antibiotics.
When using the higher target of 100% fTMIC, there were large
differences in the FTAs between the broad- and narrower-spec-
trum antibiotics (Table 4). However, changing the intermittent
infusion to a higher-dose continuous infusion improved the FTA
dramatically. For amoxicillin-clavulanic acid, this improved the
FTA from66% (1 g every 6 h) to 98% (6 g continuously) for E. coli,
and for cefuroxime, this improved the FTA from 45% (1.5 g every
8 h) to 98% (6 g continuously) for E. coli. For flucloxacillin, in
order to obtain a high FTA for oxacillin-susceptible S. aureus, the
dose needed to be increased from 1 g every 6 h (FTA, 36%) to 8 g
as a continuous infusion (FTA, 100%), and for cefepime and ce-
fazolin, the dose needed to be increased from 2 g every 12 h for
cefepime (FTA, 69%) and 1 g every 8 h for cefazolin (FTA, 77%) to
4 g continuously (FTAs, 100%).
DISCUSSION
De-escalation of antibiotic therapy, or the changing of therapy
with an empirical antibiotic to one with a narrower-spectrum an-
tibiotic, is often advocated to reduce the use of broad-spectrum
antibiotics in the hospitalized patient (3, 29). It is generally consid-
ered safe, has been associated with improved outcomes in several
observational studies, and is recommended in the 2013 Surviving
Sepsis Campaign guidelines (9, 10, 30). As such, it is often incorpo-
rated into antibiotic stewardship programs in critically ill patients
(31, 32), although in clinical practice there seem to be a number of
obstacles to its widespread use (33). In observational studies, empir-
ical antibiotics are de-escalated in roughly 15 to 50% of the patients,
depending on the definition used (9, 25, 33, 34).
In this study, we have found that for a number of pathogens, the
fractional target attainment (FTA) was higher for the empirical
broad-spectrum antibiotics meropenem and piperacillin-tazobac-
tam than for the narrower-spectrum antibiotics amoxicillin-clavu-
lanic acid, cefuroxime, flucloxacillin, cefazolin, and cefepime using
conventionaldosing.Given that theprobability that thePK/PDtarget
for somemicroorganism-antibiotic combinations will be achieved is
lower for thenarrower-spectrumalternative, de-escalationwith stan-
dard dosing may predispose selected patients to clinical failure and
recurrent infection. To the best of our knowledge, this is the first
studyof its kind to compare the achievement of therapeutic exposure
by empirical antibiotic therapy with the achievement of therapeutic
exposure by de-escalation of antibiotic therapy on the basis of popu-
lation PK models from critically ill patients. Although there is cur-
rently no evidence that subtherapeutic dosing of-lactamantibiotics
leads to treatment failure or to a higher incidence of resistance, this
has been shown for other antibiotics. For tobramycin, for example, it
has been shown that although the peak concentration/MIC is associ-
ated with themaximal effect, for the same area under the curve/MIC
value, once-daily dosing (with subsequent lower trough concentra-
tions) leads to higherMIC values than three-times-daily dosing after
2 weeks of treatment (35).
The FTA is dependent on a number of factors, and recent in-
sights into PK/PD characteristics in critically ill patients may help
us to explain these findings. Because of pathophysiological
changes in critically ill patients, such as an increased volume of
distribution and augmented renal clearance, standard dosingmay
not always lead to optimal target attainment (36, 37).Moreover, it
is also dependent on the PK/PD target (40% fTMIC for carbap-
enems versus 65% fTMIC for cephalosporins). Next, the suscep-
tibility of themicroorganism plays an important role. The suscep-
tibility of the same microorganism may vary for different
antibiotics, and similarly, the potencies of certain antibiotics
against different microorganisms may be different, even though
all microorganisms are reported to be susceptible (38). Moreover,
the PK/PD target is currently considered to be fixed; however, it
has never been investigated if the PK/PD target changes over time.
A changing PK/PD target over time, not taken into account by
dosing, could also result in treatment failure and the emergence of
resistance. Finally, an increasing proportion of ICUs are adminis-
tering meropenem and piperacillin-tazobactam as an extended or
continuous infusion, as away to increase PK/PD target attainment
(6, 20). However, these alternative modes of administration are
not used for the narrower-spectrum antibiotics, which are still
being administered as short infusions with standard doses (6).
This contrasting approach could further increase the gap in
PK/PD target attainment between empirical and de-escalated an-
tibiotic therapy.
The findings of our study may partly explain the findings of a
recent de-escalation study that could not confirm noninferiority
when comparing de-escalation to continuation of the empirical
therapy (11). Leone et al. (11) found in a randomized controlled
trial not carried out in a blind manner that antibiotic use was
higher in patients in whom therapy had been de-escalated due to
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an increased number of superinfections, about half of which were
caused by the same pathogen that caused the primary infection.
This suggests that the antibiotics used in the de-escalation arm
were less effective in eradicating the infection than the broad-
spectrum antibiotics in the comparative arm. In that study, no
details regarding dosing were reported (11).
Of the most recent de-escalation studies, only one has men-
tioned the dose and mode of administration of the initial broad-
spectrum regimen, but it did not mention these data about the
de-escalated antibiotics (11, 25–27). Another study mentioned
that “the dose and pattern of administration were in accordance
with current medical standards” (9). Dosing may be the key to
improve patient outcome, as recent data have demonstrated that
there is a correlation between the blood concentrations of -lac-
tam antibiotics and clinical outcome (6). Future de-escalation
studies should ensure that dosing and themode of administration
of the narrower-spectrum antibiotics are likely to achieve appro-
priate PK/PD targets.
We could also demonstrate that PK/PD target attainment is
drastically improved when higher dosages and different modes of
administration of the de-escalation antibiotics are used. However,
it must also be highlighted that blindly increasing the dose in all
patientsmay give rise to needlessly high concentrations in some of
them. Although -lactams are not commonly toxic, toxicity is
severe when it occurs, with seizures from high concentrations be-
ing reported previously (39–41). This wide pharmacokinetic vari-
ability suggests that the principle of one dose fits all is unlikely to
be appropriate in this patient population (42).
There are a number of limitations of the current analysis that
we would like to discuss. These results are not based on measured
concentrations from actual patients. However, we have simulated
concentrations using population pharmacokinetic models and
relevant covariates in critically ill patients. As such, the accuracy of
the results can be assumed to be acceptable, given that the same
approach was used for simulations with the empirical and de-
escalation antibiotic. The patient population simulated consisted
of patients who had normal renal function (serum creatinine con-
centration, 171 mol/liter) and did not include patients with
acute kidney injury, and therefore, these conclusions are relevant
only to this patient group. Also, there is little knowledge on which
PK/PD target should be aimed for in critically ill patients, as the
targets are derived from animal models on day 1 or 2 of antibiotic
therapy. Whether or not this PK/PD target changes over time as a
result of the changing susceptibility or the adaptive resistance of
the pathogen is also a remaining question. Moreover, there is no
time dependency of the data. In clinical practice, de-escalation is
generally performed when the patient is improving (and there-
fore, the pharmacokinetic issues associated with critical illness
may be partly normalized) and has a lower bacterial burden. This
cannot be accounted for in the modeling. Finally, only 7 antibiot-
ics were simulated, due to the unavailability of population phar-
macokinetic models of other -lactam antibiotics in critically ill
patients, although these are all commonly used agents, making
these data of significant interest to many ICU clinicians.
Conclusion. For a selection of microorganisms in which de-
escalation may be considered, the results of this simulation study
show that the probability that the PK/PD target will be achieved
was lower for the narrower-spectrum antibiotics amoxicillin-cla-
vulanic acid, cefuroxime, flucloxacillin, cefazolin, and cefepime
using conventional dosing than the broad-spectrum antibiotics
meropenem and piperacillin-tazobactam. As this may impact
clinical outcome parameters, studies that report on the results of
de-escalation strategies should accurately report the dosing of the
antibiotics used. Future research should be focused on correct
dosing not only of broad-spectrum antibiotics but also of narrow-
er-spectrum antibiotics, where higher dosages and alternative
modes of administration may be needed for patients at risk of not
achieving PK/PD targets.
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